MEDICALLY SUPERVISED OPIATE WITHDRAWAL FOR THE DEPENDENT PATIENT. An Outpatient Model



Similar documents
Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone )

Update on Buprenorphine: Induction and Ongoing Care

OVERVIEW OF MEDICATION ASSISTED TREATMENT

Neurobiology and Treatment of Opioid Dependence. Nebraska MAT Training September 29, 2011

Substitution Therapy for Opioid Dependence The Role of Suboxone. Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015

Care Management Council submission date: August Contact Information

Opioids Research to Practice

Using Drugs to Treat Drug Addiction How it works and why it makes sense

MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION

COMMUNITY BUPRENORPHINE PRESCRIBING IN OPIATE DEPENDENCE

Opioid Addiction and Methadone: Myths and Misconceptions. Nicole Nakatsu WRHA Practice Development Pharmacist

One example: Chapman and Huygens, 1988, British Journal of Addiction

EPIDEMIC 4.6 % OF INDIVIDUALS USED PAIN RELIEVERS FOR NON-MEDICAL REASONS. 1.5 MILLION YOUNG ADULTS USED PAIN RELIEVERS IN THE PAST MONTH.

Opioid Treatment Services, Office-Based Opioid Treatment

Opioids Research to Practice

How To Treat Anorexic Addiction With Medication Assisted Treatment

Naltrexone and Alcoholism Treatment Test

Buprenorphine Therapy in Addiction Treatment

Opiate Treatment for Aboriginal High School Students in Ontario

Information for Pharmacists

Medication-Assisted Treatment for Opioid Addiction

Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings

Treatment of opioid use disorders

Use of Buprenorphine in the Treatment of Opioid Addiction

OPIOIDS. Petros Levounis, MD, MA Chair Department of Psychiatry Rutgers New Jersey Medical School

Prior Authorization Guideline

Pain, Addiction & Methadone

Buprenorphine/Naloxone Maintenance Treatment for Opioid Dependence

Frequently asked questions

Buprenorphine Treatment in Primary Care

Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction. Frequently Asked Questions

KAP Keys. For Physicians. Based on TIP 40 Clinical Guidelines for the Use of Buprenorphine in the Treatment. of Opioid Addiction

Science and Treatment Prescription Drug Addiction Treatment. Karen Miotto, M.D. David Geffen School of Medicine

The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office

OTC Abuse. Dr. Eman Said Abd-Elkhalek Lecturer of Pharmacology & Toxicology Faculty of Pharmacy Mansoura University

Patients are still addicted Buprenorphine is simply a substitute for heroin or

Considerations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT

Dependence and Addiction. Marek C. Chawarski, Ph.D. Yale University David Metzger, Ph.D. University of Pennsylvania

Treatment Approaches for Drug Addiction

Treatment Approaches for Drug Addiction

Dosing Guide. For Optimal Management of Opioid Dependence

Teen Misuse and Abuse of Alcohol and Prescription Drugs. Information for Parents

Assessment and Management of Opioid, Benzodiazepine, and Sedative-Hypnotic Withdrawal

Office-based Treatment of Opioid Dependence with Buprenorphine

Opiate Abuse and Mental Illness

What is Addiction and How Do We Treat It? Roger D. Weiss, M.D. Professor of Psychiatry, Harvard Medical School Clinical Director, Alcohol and Drug

Treatment of Prescription Opioid Dependence

Guidelines for Titration onto Buprenorphine in Opioid Dependence

Financial Disclosures

Medication-Assisted Addiction Treatment

Opioid/Opiate Dependent Pregnant Women

The ABCs of Medication Assisted Treatment

ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines

EPIDEMIOLOGY OF OPIATE USE

MEDICAL ASSISTANCE BULLETIN

UNIT VIII NARCOTIC ANALGESIA

TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION

A prisoners guide to buprenorphine

DrugFacts: Treatment Approaches for Drug Addiction

ARCHIVED BULLETIN. Product No L SEPTEMBER 2004 U. S. D E P A R T M E N T O F J U S T I C E

Treatment and Interventions for Opioid Addictions: Challenges From the Medical Director s Perspective

Benzodiazepine Detoxification and Reduction of Long term Use

Prescription Drug Abuse

DSM 5 Opioid Related Disorders. Dr. Phil O Dwyer Oakland University Brookfield Clinics

Guidelines for the Prescribing, Supply and Administration of Methadone and Buprenorphine on Transfer of Care

Joel Millard, DSW, LCSW Dave Felt, LCSW

Substance Use Disorder Overview. Presented By Ecole J. Barrow-Brooks M.Ed & Darlene D. Owens MBA, LBSW, CADC, ADS

1. According to recent US national estimates, which of the following substances is associated

Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery

Like cocaine, heroin is a drug that is illegal in some areas of the world. Heroin is highly addictive.

FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma

Opioid Agonist Therapy: The Duration Dilemma Edwin A. Salsitz, MD, FASAM Mount Sinai Beth Israel, New York, NY March 10, 2015

Pain and problem drug use

Tolerance and Dependence


Southlake Psychiatry. Suboxone Contract

Frequently Asked Questions (FAQ s): Medication-Assisted Treatment for Opiate Addiction

IN THE GENERAL ASSEMBLY STATE OF. Ensuring Access to Medication Assisted Treatment Act

MEDICAL POLICY Treatment of Opioid Dependence

Identifying Individuals with a Dual Diagnosis and Substance Misuse

Prescription Drug Addiction

Addiction Medicine for FP / GP. Dr. Francisco Ward, DABPMR/PM SetonPainRehab.com setonpr@gmail.com

Opioid Treatment Agreement

2) Recurrent emotional abuse. 3) Contact sexual abuse. 4) An alcohol and/or drug abuser in the household. 5) An incarcerated household member

PRESCRIPTION DRUG ABUSE prevention

The Truth About Suboxone Russell Ferstandig, M.D. Diplomate American Board of Addition Medicine 2014, Russell Ferstandig, M.D., All Rights Reserved

The Results of a Pilot of Vivitrol: A Medication Assisted Treatment for Alcohol and Opioid Addiction

MEDICAL ASSISTANCE BULLETIN

4/13/15. Case 1. COWS = Clinical Opioid Withdrawal Scale. Special Populations

What is Addiction? DSM-IV-TR Substance Abuse Criteria

Practice Protocol. Buprenorphine Guidance Protocol

Management of benzodiazepine misuse

Medications Used in the Treatment of Addiction Developed by Randall Webber, MPH. Alcohol Withdrawal

Transcription:

MEDICALLY SUPERVISED OPIATE WITHDRAWAL FOR THE DEPENDENT PATIENT An Outpatient Model

OBJECTIVE TO PRESENT A PROTOCOL FOR THE EVALUATION AND TREATMENT OF PATIENTS WHO ARE CHEMICALLY DEPENDENT ON OR SEVERLY ABUSING OPIATES.

EVALUATION DEFINE THE CRITERIA WHICH IS USED TO ACCURATELY DIAGNOSE THE CONDITION

DSM-IV CRITERIA FOR SUBSTANCE DEPENDENCE DEFINITION: A maladaptive pattern of substance use, leading to clinically significant impairment, as manifested by three of the following within the past three months:

1) Increased tolerance of substance 2) Withdrawal Syndrome 3) Preoccupation 4) Reduction in social, occupational and/or recreational activities 5) Continued use, despite consequences

INCREASED TOLERANCE INCREASED AMOUNTS OF DRUG NEEDED TO ACHIEVE DESIRED EFFECT DIMINISHED EFFECT WITH CONTINUOUS USE OF THE SAME AMOUNT OF DRUG

PATTERN OF USE Substance is used longer and in larger quantities than initially intended. Repeated efforts to quit, control or cutback the use of substance Switching from prescription Opiates to illicit Heroin; a very common scenario in this age group due to affordability. Often begins with single-dose Vicodin/Percocet mixed with alcohol. Progresses to long-acting Oxy product.

PREOCCUPATION Once these patients progress to daily HEROIN use, they typically buy it one day at a time. A great deal of time is invested in activities necessary to obtain the drug Other interests and ambitions are neglected (I.e., Education, Sports, Scholarships, friends, self, friendships, relationships, etc) Daily behavior is dictated by withdrawal symptoms from waking up to going to sleep Total focus of the day is PREVENTION OF WITHDRAWAL. Typically, at this point, there is little Eupophoria associated with using.

PREOCCUPATION (CONT D) REPEATED EFFORTS TO QUIT, CONTROL OR CUT-BACK THE USE OF SUBSTANCE. SWITCHING FROM PRESCRIPTION OPIATES TO ILLICIT HEROIN; A VERY COMMON SCENARIO IN ADOLESCENT AGE GROUP DUE TO AFFORDABILITY. OFTEN BEGINS WITH SINGLE-DOSE VICODIN/PERCOCET MIXED WITH ALCOHOL

LOSS OF CONTROL REPEATED EFFORTS TO QUIT, CONTROL OR CUT BACK THE USE OF SUBSTANCE IS LESS COMMON IN PATIENTS. MOST ADOLESCENTS SETTLE INTO ONE FIXED DOSE 1-2GM HEROIN OR 80MG OXYCONTIN TID. HEROIN IS USUALLY SMOKED OR INJECTED. OXYPRODUCTS ARE GENERALLY CHEWED THEN IT PROGRESSES TO INTRANASAL FOR MORE RAPID EFFECT

USE DESPITE ADVERSE CONSEQUENCES SUBSTANCE USE CONTINUES IN THE FACE OF PHYSICAL AND EMOTIONAL BREAK-DOWN DEPRESSION RECURRENT WITHDRAWAL SYMPTOMS, LEGAL COMPLICATIONS COMMON DUE TO POOR IMPULSE CONTROL IN THE FACE OF OBVIOUS RISK

WITHDRAWAL Characteristic Opiate Withdrawal Syndrome measured by the COWS Tool Same or related substance is taken to relieve or avoid Withdrawal Syndrome

EVALUATION Comprehensive psychosocial history to screen for co-occurring psychopathology Anxiety disorders(ocd,agoraphobia, anorexia/bulemia,gad,social Phobia) ADD/ADHD,ODD,Antisocial Disorders,Sociopathy Bipolar Disorder/Depression Sexual/Physical Abuse history

EVALUATION (cont.) Comprehensive Medical History with baseline Urine Drug Screen Chronic pain,trauma history,ibs or IBD Autoimmune disorders,chronic Fatigue Syndrome Sleep Disorders(REM behavioral Disorder-RBD) Parasomnias, Circadian Rhythm Disorder

EVALUATION (cont d) Determine Stage of Substance Abuse Disorder Potential for abuse(reduced impulse control with availability of substances and peer pressure Experimentation(learning euphoria, few consequences,minimal behavior change Regular use(seeking euphoria using harder drugs,behavioral changes and some consequences,using along,buying or stealing drugs Regular use-preoccupation and loss of control,multiple consequences and risk taking. Adolescents are often estranged from straight friends Burnout-use of drugs to feel normal, guilt, shame, withdrawal, remorse, depression, suicidal thoughts or attempts

PHYSICAL EXAM Routine Medical Examination Clinical Opiate Withdrawal Scale (COWS)

COWS Objective measurement of the degree of opiate withdrawal for the purpose of determining the severity of withdrawal as well as when to start Buprenorphine Therapy. This is an 11-category tool.

COWS Pulse, Sweating, Restlessness, Pupil Size, Bone or Joint Aches, Runny nose or tearing, GI upset, Tremor, Yawning, anxiety or Irritability, Gooseflesh. Each numbered 1-5 then totaled 5-12=mild,13-24=moderate,25-36=moderately severe, >36=Severe

COWS Once a patient reaches a level of 15 or higher, it is safe to start Buprenorphine Therapy with Subutex(not Suboxone due to Naloxone component) 8-10% of Naloxone absorbed subliqually vs. 50% of Buprenorphine 4:1 Combination ideal ratio to discourage diversion yet be effective(8/2 and 2/.5)

BUPRENORPHINE Pharmacokinetics/Pharmacodynamics 3 key aspects of this medication 1.High Affinity for Mu Receptor 2.Long duration of action 3.Slow dissociation Partial agonist= partial stimulation at mu receptor and an Antagonist at Kappa which results in a decreased opiate effect the higher the dose.

BUPRENORPHINE Important to spend time educating the patient (and caregiver) about the nature of this medication which will improve compliance and reduce relapse Many misconceptions about it s effects Describe the 3 phases of treatment Induction /Stabilization/ Maintenance

INDUCTION Patients are divided into 2 catagories prior to Induction 1.Short-Acting Opioids(Heroin,Oxycodone, Hydro-codone, etc 2.Long-Acting Opioids(Methadone, Oxy contin,ms contin,opana ER) (This is more problematic due to having to wait longer to go into withdrawal)

INDUCTION Instruct Patient on how to take a subliqual tablet Administer patient s first dose(usually 4mg) and wait Onset usually 20-40 minutes(anxiety and restlessness are the first to go) Observe for 2 hours and re-dose 2-4mg as needed

INDUCTION Key is to dose patient and have them wait first for relief then for withdrawal symptoms to return, then re-dose 2-4mg. Maximum dose for first day should be 8-12mg On Day #2, Total what the patient needed on day one and administer in 4mg increments throughout the day waiting after each dose to see how long it lasts Maximum dose for Day #2 should be 16mg

INDUCTION Day #3- Total the dose given on day 2 and dose in 4-8mg increments again waiting after each dose to determine how long it works. If patient is coming off Long-acting Opioids, must wait longer to induce and may need adjuctive meds

STABILIZATION Once the total daily dose is determined, start pre-empting the return of withdrawal symptoms so as not to reinforce pain/drug relief EXAMPLE: 8mg at 8am then normally symptoms return at 4pm, then start taking second dose at 3pm. Repeat this protocol for 3-4 days so patient never physically feels the need to take meds

STABILIZATION Very important not to reward patient with the drug following effective Induction and early Stablization. With adolescent and adult population, administration and responsibility of securing the medication should be that of the adult or caregiver Random drug testing begins(can differentiate general opiates from oxycodone and buprenorphine

STABILIZATION Minimal time for stablization should be three months to create a homeostasis at the mu receptor in order to allow the pschosocial and nutritional/health components of recovery to have a chance to be effective-otherwise poor prognosis Without a NeuroBiological Stablization the chance for a meaningful recovery is bleak

MAINTENANCE This phase of therapy should not apply to adolescent patients since there is no reason complete abstinance from opiates should not be the goal, unlike some adults

BUPRENORPHINE TAPER Ideal rate of weaning should be 1-2mg every 2 weeks(suboxone should be used during stablization and return to subutex for taper Cognitive Behavioral Therapy plays an important role Must identify and address the reason patient chose opiates as their drug of choice

CONCLUSION The epidemic of adolescent and adult opiate addiction can be effectively and safely treated on an outpatient basis if there is sufficient expertise of prescribing,development of a trusting doctor/patient relationship and a supportive caregiver role model. Drug testing is also a key factor if it is presented as a therapeutic tool and not a punishment It is also important to reward compliance with more independence